ELECTIVE MECHANICAL SUB PULMONARY SUPPORT - THE FINAL FRONTIER OF SINGLE VENTRICLE PALLIATION-Reference-Cited by-同舟云学术

ELECTIVE MECHANICAL SUB PULMONARY SUPPORT - THE FINAL FRONTIER OF SINGLE VENTRICLE PALLIATION

Published:2021-09-15 Issue: Volume: Page:156-157
ISSN:
Container-title:GLOBAL JOURNAL FOR RESEARCH ANALYSIS
language:en
Short-container-title:

Author:

Radhakrishnan Pradeep Kumar¹,Ambat Gayathri Ananyajyothi²,Victor Sitaramaswamy³,Nazer Y A⁴,Sharma Rajesh⁵

Affiliation:

1. Ms, MCh CTVS AIIMS, Postdoctoral Fellow CTVS, Postdoctoral Fellow ECMO, CPDH IISc, FACC, FIACS, Global MBA Lond, Mentor World Innovation Hub, Chief Division of Cardiothoracic and Vascular Surgery, Gitam University.

2. Medical Student, GIMSR, Gitam University, Sachin Reddy MBBS, GIMSR, Gitam University.

3. Medical Student, GIMSR, Gitam University.

4. MS MCh AIIMS, Director Travancore Heart Institute and Travancore Medical College, Kerala.

5. MS MCh AIIMS,Fellow Boston Childrens Hospital and Miami Florida, VADBerkely Institute USA, Chief Division of Pediatric Cardiac Surgery,Jaypee Hospital Noida

Abstract

Sophisticated technology advances are fast taking taking shape to provide long term destination therapy mechanical circulatory assistance. Sai Spandan total articial heart with hybrid BSRM core with dual motor and controls, virtual t technology is one such over the horizon. The promise is of better quality of life and longevity. Transcutaneous charging of fully implantable models would very soon revolutionize cardiac surgical treatment modalities. The nal frontier in a failing Fontan is sub pulmonary mechanical assistance. We take a short look into the issues and possibilities. The research gap exists for the innovator in this eld.

Publisher

World Wide Journals

Reference16 articles.

1. d’Udekem Y, Rychik J. Towards the goal of achieving a normal duration and quality of life after Fontan operation: creation of the international Fontan interest group (I-FIG), an international collaborative initiative dedicated to improving outcomes. Int J Cardiol. 2017; 245:131-4

2. Schilling C, Dalziel K, Nunn R, Du Plessis K, Shi WY, Celermajer D, et al. The Fontan epidemic: population projections from the Australia and New Zealand Fontan registry. Int J Cardiol. 2016; 219:14-9

3. Pundi KN, Johnson JN, Dearani JA, Pundi KN, Li Z, Hinck CA, et al. 40-year follow-up after the Fontan operation: Long-term outcomes of 1,052 patients. J Am Coll Cardiol. 2015; 66:1700-10.

4. Elder RW, McCabe NM, Hebson C, Veledar E, Romero R, Ford RM, et al. Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study. Int J Cardiol. 2013; 168:3764-9

5. Malekzadeh-Milani S, LadouceurM, Iserin L, Boudjemline Y. Percutaneous valvulation of failing Fontan: rationale, acute effects and follow-up. Arch Cardiovasc Dis. 2014; 107:599-606